Active Ingredient: GLIBENCLAMIDE
Glibenclamide a specific blocker of ATP-sensitive potassium (KATP) channels used in type 2 diabetes, significantly prolongs ventricular repolarization and increases ventricular heterogeneity. In a randomized clinical study comparing glyburide to metformin in 30 diabetic patients over 2 months, glyburide therapy was associated with a highly significant increase in rate-corrected QT interval (QTc) from 433±24 ms to 467±24 ms (p<0.001). Furthermore, glyburide significantly increased both QT dispersion (QTd, from 24±16 to 60±22 ms, p<0.001) and corrected QT dispersion (QTcd, from 35±18 to 68±21 ms, p<0.001). The increased dispersion induced by glyburide represents a pathophysiological substrate that may elevate the risk of ventricular arrhythmias and sudden cardiac death.
https://doi.org/10.1016/s0002-9149(02)02776-5